logo
logo
Bruker Corporation

Bruker Corporation

NASDAQ•BRKR
CEO: Dr. Frank H. Laukien Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2000-08-04
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
連絡先情報
40 Manning Road, Billerica, MA, 01821, United States
978-663-3660
www.bruker.com
時価総額
$6.32B
PER (TTM)
-302.0
31.5
配当利回り
0.5%
52週高値
$56.22
52週安値
$28.53
52週レンジ
47%
順位30Top 19.5%
5.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$860.50M-0.45%
直近4四半期の推移

EPS

-$0.41-252.26%
直近4四半期の推移

フリーCF

-$54.10M-1032.76%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth 9M YTD Total revenue reached $2.46B, marking a 3.0% increase over prior period, driven by acquisitions and service revenue.
CALID Segment Revenue Surge BSI CALID revenue increased $105.7M, up 13.7% driven by ELITechGroup and molecular diagnostics volume growth.
Preferred Stock Issuance Completed Issued 2.76M Series A Mandatory Convertible Preferred Stock shares, raising $669.5M net proceeds for debt repayment.
Cash Position Improved Sequentially Ending cash balance $297.3M, up $110.6M sequentially, despite $(95.7)M used in operating activities year-to-date.

リスク要因

Significant Goodwill Impairment Charge Recorded $96.5M goodwill impairment charge across BSB and AUT units due to fair value falling below carrying amount.
Operating Income Swings Negative Operating income swung to a $(8.1)M loss for nine months, compared to $181.0M income last year period.
Gross Margin Under Pressure Total gross margin fell to 45.9% from 48.4% due to increased restructuring costs and U.S. tariff impacts.
Operating Cash Flow Negative Net cash used in operating activities was $(95.7)M for nine months, compared to $61.3M provided in 2024.

見通し

Cost Savings Initiative Planned Announced cost savings initiative targeting $100M to $120M annual reduction starting in 2026 across all business parts.
Debt Repayment Utilizing Proceeds Used $669.5M proceeds from preferred stock to fully repay 2019 term loan and outstanding revolving credit balance.
Monitoring Macroeconomic Uncertainties Management monitors geopolitical tensions, tariffs, and funding delays, which may cause future goodwill impairment charges.
Finalizing Acquisition Valuations Finalized valuation for Recipe acquisition; processing tax adjustments for other acquisitions, impacting goodwill balances.

同業比較

売上高 (TTM)

Bausch + Lomb CorporationBLCO
$4.98B
+6.2%
Bruker CorporationBRKR
$3.44B
+6.1%
Teleflex IncorporatedTFX
$3.19B
+5.4%

粗利益率 (最新四半期)

Krystal Biotech, Inc.KRYS
94.2%
+2.2pp
TG Therapeutics, Inc.TGTX
82.6%
-6.3pp
Glaukos CorporationGKOS
78.4%
+1.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
KRYS$7.85B39.419.4%0.8%
PCVX$7.80B-11.4-21.1%2.7%
CHE$6.59B23.624.4%8.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-4.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月12日
|
EPS:$0.65
|
売上高:$964.61M
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $860.50M-0.5%
    |
    EPS: $-0.41-252.3%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $797.40M-0.4%
    |
    EPS: $0.05+0.0%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $801.40M+11.0%
    |
    EPS: $0.11-68.6%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $3.37B+13.6%
    |
    EPS: $0.76-74.0%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $864.40M+16.4%
    |
    EPS: $0.27-55.0%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $800.70M+17.4%
    |
    EPS: $0.05-87.2%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $721.70M+5.3%
    |
    EPS: $0.35-32.7%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $2.96B+17.1%
    |
    EPS: $2.92+46.0%
    予想を上回る